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Numerous investigators,  most notably Rammelkamp  (1) and  Stollerman  (2), 
have established that acute poststreptococcal glomerulonephritis  (APSGN) ~ re- 
sults  from  infection  with  a  limited  number  of serological  types  of group  A 
streptococci. However, even within a given nephritogenic type, it has been noted 
that not all strains cause nephritis, thereby suggesting that only certain strains of 
these nephritogenic  types elaborate a streptococcal product that may be respon- 
sible for the initiation of APSGN. 
Histological  data,  in  association  with  immunofluorescent  studies  of a  large 
number of glomerular  biopsies in  APSGN have demonstrated  the presence of 
streptococcal antigen(s)  in  the glomeruli.  Seegai et al.  (3) have suggested that 
antigen(s) localized in the glomerular wall of APSGN patients  were part of the 
streptococcal cell wall; whereas Lange et al. (4) have suggested that a cytoplasmic 
entity known as endostreptosin was the antigen in question. In a similar approach, 
Ahmed  et  al.  (5)  suggested  that  the  putative  agent  resides  also  within  the 
streptococcal cell  and  could be detected only in  the  supernatant  of disrupted 
streptococci. Vogt et al. (6, 7) reported that cationic, extracellular streptococcal 
antigens were observed in 8 out of 18 renal biopsies from patients with APSGN 
and suggested that APSGN was initiated by in situ immune complex formation 
with these cationic antigens. 
ViUareal et al.  (8) reported that group A  streptococci isolated from patients 
diagnosed as having  developed APSGN secreted an  extracellular  protein  that 
had  a  subunit  of Mr  46,000  as  determined  by SDS-PAGE.  This  protein  was 
generally not secreted by streptococcal strains  isolated from patients who were 
diagnosed as not having APSGN. Because of this association between isolate and 
disease, this protein was called the nephritis  strain-associated  protein  (NSAP). 
Villareal  et  al.  (8)  also showed  that  several  M  types of group  A  streptococci 
representing  both  the  classical  skin  and  throat  strains  elaborated this  protein. 
Polyclonal rabbit antibody prepared  to this extracellular  protein and used as a 
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histological probe indicated that the NSAP was present in  14 out of 21  kidney 
biopsies of patients with APSGN. Ohkuni et al. (9), using an electrophoretically 
purified  NSAP  preparation,  showed  that  >95%  of APSGN  patients  exhibited 
antibody  to  this  protein,  while  only  20%  of either  acute  rheumatic  fever or 
impetigo sera contained antibody to NSAP. 
We have reassessed the relationship between the presence of NSAP in group 
A streptococcal strains in relation to the source of the strain. Using mAb specific 
to NSAP and a  new solid-phase ELISA, the original observations of Villareal et 
al.  (8) were confirmed. In addition, a  method of isolating and purifying NSAP 
in  sufficient  amounts  for  structural  and  biochemical  studies  is  presented.  It 
became apparent that NSAP is a major extracellular protein of these streptococ- 
cal strains isolated from APSGN patients. Preliminary structural and biochemical 
data on purified NSAP indicated that this protein possesses both structural and 
biochemical properties identical to streptokinase. 
Materials and Methods 
Growth Medium.  The chemically defined medium of van de Rijn et al. (10) was used 
throughout this study. The medium was prepared by sequential addition of solubilized 
amino acids, vitamins, purines and pyrimidines to buffer salts in the order recommended 
by van de Rijn  et al.  (10),  with  the exception that  mineral salts  were added last.  For 
medium not to be used immediately, glucose, NaHCO3 and cysteine-HCl were added just 
before use.  All  solutions, including complete medium  were filter sterilized by passage 
through 0.22 um cellulose triacetate Metricel membranes (Fischer Scientific, Pittsburgh, 
PA).  All  medium  components  were  the  best  grade  possible,  purchased  from  Sigma 
Chemical Co., St. Louis, MO. 
Streptoccal Strains.  24 strains of Streptococcus pyogenes group A, originally described by 
Villareal et al., (8 and Table I) were used in this study. ! 2 strains had been isolated from 
patients who had been diagnosed as having APSGN, and  !2 strains had been isolated 
from patients  diagnosed  as having suppurative and/or nonsuppurative sequelae other 
than APSGN. All strains were reconstituted from the lyophilized state on sheep blood 
agar; single colonies were selected and inoculated into the chemically defined medium 
(CDM).  Adaptation to growth in CDM was accomplished by repeated subculture in this 
medium. 
SDS-PAGE.  All electrophoretic analyses were studied by SDS-PAGE according to the 
procedure of Laemmli (I 1). Electrophoresis was carried out on 10% polyacrylamide gels 
with a 5% stacking gel, at a constant current of 50 mA. Phosphorylase b (97.4 kD), BSA 
(68 kD), ovalbumin (45 kD), glyceraldehyde dehydrogenase (36 kD), carbonic anhydrase 
(29  kD),  and  13-1actoglobulin (18.4  kD)  were  used as  molecular mass  standards.  Both 
samples and standards were mixed with equal portions of sample buffer containing 2% 
(wt/vol) SDS,  2% (vol/vol) 2-ME,  30% (vol/vol)glycerol, 0.01%  (wt/vol)bromophenol 
blue, and were boiled for 2 rain before application to gel. 
Immunological  Analyses.  Samples  were analyzed for the  presence of NSAP  by two 
procedures. The methods were either Western  blot analysis  or dot blot analysis.  For 
Western blot analysis,  proteins resolved by SDS-PAGE were transferred to nitrocellulose 
membranes (BA85; Schleicher and Schuell, Keene, NH) according to the procedure of 
Towbin et al.  (12), with a transfer time of 1 h at  1 A. After transfer, the nitrocellulose 
membrane was incubated for at least  1 h at room temperature with two changes of 10 
mM  Tris-HCl buffer, pH  8.2,  containing 0.5%  (vol/vol) Tween 20,  0.5  M  NaCI,  and 
0.04%  (wt/vol) sodium azide  (TTB buffer) to block  remaining protein  binding sites. 
Primary antibody, diluted in  10 mM Tris-HCI buffer, pH 8.2, containing 0.15.M NaCI, 
0.05% (vol/vol) Brij 35, and 0.02% (wt/vol) sodium azide (TBI buffer) was applied and 
allowed to react for 2 h at room temperature. The membrane was then washed three 
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conjugated  to bovine calf intestine  alkaline phosphatase (Type VII-S; Sigma Chemical 
Co.) by the procedure of Avrameas et al. (13), diluted in TBI buffer, was applied. After 
incubation at room temperature for 1 h, the membrane was washed four times at 5-min 
intervals with TTB buffer, followed by several rinses with 50 mM Tris-HC! buffer, pH 
10.0,  containing  3  mM  MgCI2.  The  reaction  was  developed  by addition  of enzyme 
substrate solution,  which  was prepared by adding  to 9  ml Tris-HCl buffer,  pH  10.0, 
containing 3 mM MgCI~,  1 ml of 0.1%  (wt/vol) nitroblue tetrazolium (Sigma Chemical 
Co.) in distilled water, and 100 t~l of 0.05% (wt/voi) 5-bromo-4-chloro-indolyl phosphate 
(Sigma Chemical Co.) in anhydrous dimethylformamide (Pierce Chemical Co., Rockford, 
IL). After development, the reaction was stopped by rinsing with distilled water.  Mem- 
branes were dried at room temperature and stored between acetate sheets. 
For  dot  blot  analysis,  50  #i  aliquots  of samples to  be  tested  were  pipetted  onto  a 
nitrocellulose membrane (BA85, Schleicber and Schuell) encased within a 96-well Minifold 
Apparatus (Schleicher and Schueil). After drying, the membrane was removed from the 
chamber, blocked, and probed as described above for Western blot analysis. 
ELISA was performed according to Voller et al. (14). Purified antigen was immobilized 
with carbonate buffer to Immulon II polystyrene microtiter wells (Dynatech Laboratories, 
Alexandria, VA). After binding and blocking with 0.05% Brij 35 (vol/vol) in 10 mM Tris- 
HC1 buffer, pH 7.5, antisera diluted in TBI buffer were added. After incubation for 2 h 
at 37°C,  plates were washed with blocking buffer. Signal antibody, either goat F(ab)'2 
anti-rabbit IgG(Fc) antibody or goat F(ab)'2 anti-mouse IgG (H and L chains) antibody, 
conjugated to bovine intestinal  alkaline phosphatase by the method of Avrameas et al. 
(13), diluted in TBI buffer, was added to appropriate wells and incubated for 2 h at 37 ° C. 
After washing with 0.05% Brij 35 (vol/vol) Tris-HCI buffer, pH 7.5, 0.1 M diethanolamine 
buffer, pH  9.8,  containing  1 mM  MgCI~ and p-nitrophenyl phosphate (1  mg/ml) was 
added.  The  reaction  mixture  was  incubated  at  37°C  for  30  rain,  at  which  time  the 
absorbance was  recorded  at  405  nm  using a  Titerteck  Multiscan,  Flow  Laboratories, 
McLean, VA. All assays were performed in triplicate. 
Immunological Reagents.  Murine mAb against NSAP (mAb-NSAP) isolated from strain 
A374, was prepared from the procedure described by Buskirk et al. (15). 
Rabbit polyclonal antibody against purified NSAP isolated from Streptococcus pyogenes, 
group A, strain A374 was prepared as follows. 200 ug purified (see below) NSAP in CFA 
was administered intradermally at multiple sites into the scapular region of New Zealand 
white rabbits. After 30 d, animals were given 100 #g purified NSAP in IFA by intramus- 
cular injection. When antibody titers to NSAP were sufficiently high, as measured by the 
indirect enzyme immunoassay (see above), animals were bled, and sera processed for Ig 
isolation and purification by ammonium sulfate precipitation followed by chromatography 
on protein A-Sepharose 4 B (Pharmacia Fine Chemicals, Piscataway, N  J) as described by 
Hjelm and Sjoquist (16). 
Rabbit polyclonal antibody to purified streptokinase isolated from Group C streptococ- 
cus, strain H46 was a generous gift from Professor Stig Holm, University of Umea, Umea, 
Sweden. 
Analysis of Culture Supernatants for Presence of NSAP.  Streptococcal strains originally 
described by Villareal et al. (8) were cultured in 100 ml of CDM in 500 ml nephelometer 
flasks.  Each culture flask was inoculated with organisms to an OD of 0.05 (550 nm) and 
incubated at 37 ° C with constant gyratory stirring at 50 rpm. 10-ml aliquots were removed 
at intervals representing the early log, exponential,  late log, early stationary, and late 
stationary phases of growth. Cells were removed by centrifugation at 10,000 g for 15 min 
at 4°C.  Supernatants were filtered through 0.22 ~m cellulose triacetate Metricel mem- 
branes and protein precipitated by addition of a one-fifth volume of 60%  (wt/vol) cold 
TCA. After centrifugation at  12,000 g for 5 rain, pellets were washed and neutralized 
with cold 95% (vol/vol) ethanol containing 5% (vol/vol) 2  M sodium acetate and 0.01% 
(wt/vol) phenol red. Pellets were resuspended in 50 tA distilled water and an equal volume 
of SDS-PAGE  sample buffer was added.  Samples were  then  analyzed by SDS-PAGE. 
Proteins  were transferred  to  nitrocellulose  membranes and  subsequently  probed  with 
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Isolation  and  Purification  of NSAP.  Strain  A374,  adapted  to  growth  in  CDM,  was 
inoculated into 2-liter volumes of CDM to an initial OD of 0.05 (550 nm). Cultures were 
grown at 37°C  in roller bottles (3027;  Falcon Labware, Oxnard,  CA) and rotated at  1 
rpm. The pH of the culture was monitored by sterile removal of 10-ml aliquots at hourly 
intervals; a pH of 6.8 was maintained by addition of sterile 5 N NaOH. At early stationary 
phase of growth, iodoacetamide (1  mg/ml) and PMSF (1  raM) were added.  The culture 
was centrifuged at 10,000 g for 25 rain at 4°C; the supernatant was decanted and filtered 
through a 0.22 #m cellulose triacetate Metricel membrane. Solid ammonium sulfate (Type 
III; Sigma Chemical Co.) was added to the filtered supernatant to a final concentration 
of 70%  saturation.  After stirring at  4°C  for  18  h,  the  suspension  was centrifuged at 
10,000 g at 4°C for 25 min. The pellet was washed twice with 70% saturated ammonium 
sulfate. The washed precipitate was suspended in 50 mM Tris-HCl buffer, pH 7.5, and 
dialyzed against several changes of same buffer until all traces of ammonium sulfate were 
removed. Residual sulfate in dialysate was tested by adding  100 #1  1% (wt/vol) barium 
acetate, and 200 #1 1 N HCI to 1 ml dialysate. 
Dialyzed material was applied to a  1.5  x  20 cm column of DEAE-Sepharose 6  B-CI 
(Pharmacia  Fine  Chemicals) equilibrated  with  50  mM  Tris-HCl buffer, pH  7.5.  After 
application of sample and elution with four column volumes of 50 mM Tris-HCi buffer, 
pH  7.5,  NaCI  gradient  (0-0.5  M)  in  50  mM  Tris-HCl buffer,  pH  7.5,  was  applied. 
Fractions were collected and assayed for absorbance at 280  nm and NSAP by dot blot 
analysis using  mAb-NSAP.  Fractions  that  were  mAb-NSAP-reactive were pooled and 
dialyzed against  25  mM piperazine-HCl buffer, pH 5.5.  After dialysis,  the sample was 
applied  to a  0.7  x  50  cm column of Polybuffer Exchanger (PBE 94;  Pharmacia Fine 
Chemicals) previously equilibrated  with  25  mM  piperazine-HCl buffer,  pH  5.5.  After 
application of sample and elution with five vol of start buffer, 12 vol of a  1:10 dilution of 
Polybuffer 74 (Pharmacia Fine Chemicals), titrated to pH 4.0 with  1 N HCI were added. 
The column was eluted at a constant flow rate of 15 cm/h. Fractions were monitored at 
280 nm and by dot blot analysis using mAb-NSAP as a probe. Fractions containing NSAP 
were pooled and dialyzed against 0.1  M NaHCO3, pH 8.0, before lyophilization. 
Amino Acid Analysis.  Quantitative amino acid analysis was performed on  1 nmol of 
lyophilized purified NSAP. Samples were hydrolyzed in 6 N HCI containing 1% (wt/vol) 
phenol at 110°C for 22 h in evacuated sealed tubes. Analysis was performed on a Waters 
Pico-tag HPLC Systems. 
Amino-terminal Sequence Analysis.  Amino-terminal sequence analysis was performed on 
2.4  nmol purified  NSAP by automated  Edman degradation  on an Applied Biosystems 
Gasphase  Sequencer  (Model  470A).  PTH-amino  acids  were  identified  by  HPLC  as 
described by Manjula et al.  (17). 
Biochemical  Assays.  Plasminogen  activation  was  studied  by  the  spectrophotometric 
method of Jackson et al. (18) as adapted from the method of Radcliffe and Heinze (19). 
In  this  method,  the  plasmin-specific synthetic  tripeptide  substrate,  n-Val-Leu-Lys-p-ni- 
troanilide (Sigma Chemical Co.) is cleaved by plasmin to release p-nitroanilide, which is 
measured at an absorbance of 405  nm.  Human plasminogen was obtained from Sigma 
Chemical Co. Assays were. performed in 96-well microtiter plates (Dynatech Laboratories, 
Alexandria, VA). To a microwell were added 10 #1 of purified NSAP (1 t~g/ml) or purified 
streptokinase isolated from group C streptococcus H46A (Sigma Chemical Co.) (1 #g/ml) 
in 0.05  M Tris-HCl buffer, pH 7.5,  containing 0.5%  (wt/vol) BSA,  20 #1 50 mM Tris- 
HCI buffer, pH 7.5, and 20 #1 human plasminogen (0.5 mg/ml) in 50 ml Tris-HCI buffer, 
pH 7.5,  containing 0.5%  (wt/vol) BSA. After incubation at 37°C  for  15  rain,  30 #1 of 
substrate solution were added, which was prepared just before use by mixing 100 #1 of n- 
Val-Leu-Lys-p-nitroanilide (5 mg/ml in distilled water) with 150 #1 1.77 M NaCi in 0.032 
M Tris-HCI buffer, pH 7.5. The reaction mixture was incubated at 37°C. The reaction 
was ended by addition of 200 #1 of 0.5  M acetic acid.  The absorbance was read at 405 
mm  using  a  Titerteck  Multiscan,  Flow  Laboratories,  McLean,  VA.  All  assays  were 
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Results 
Analysis of Culture Supernatants  with mAb-NSAP.  When the culture superna- 
tant  of Group  A  streptococcus strain  A374  was analyzed by SDS-PAGE and 
Western blot,  NSAP (46  kD) appeared in  the early log phase  of growth and 
continued to be secreted throughout the growth of the culture (Fig. 1). However, 
as the culture entered late log phase of growth, a second protein appeared (43 
kD) that  was also recognized by the  mAb prepared against the intact 46  kD 
molecule; both polypeptides possessed the epitope to which the mAb-NSAP was 
directed. As the culture progressed from the late  log phase  to the stationary 
phase of growth, the pH dropped from 7.0 to 5.5. This decrease in pH correlated 
with  emergence  of  the  43  kD  segment.  When  the  pH  of the  culture  was 
maintained at 6.8  by addition of NaOH the 46  kD molecule did not undergo 
degradation. When 24 of the streptococcal isolates described by Vitlareal et al. 
(8) were analyzed by Western blot analysis, a similar pattern of degradation of 
the intact NSAP was observed. From Table I, the most interesting observation 
was that certain strains isolated from APSGN patients would excrete intact NSAP 
for a period of time, then cease, while others would continue to secrete NSAP 
as the intact 46 kD species with little or no degradation to the 43 kD (or smaller) 
fragments. 
Isolation of  NSAP.  When the ammonium sulfate precipitate of a 2-liter culture 
supernatant of strain A374 grown to early stationary phase of growth was applied 
to  a  DEAE-Sepharose 6  B  anion-exchange column and  eluted with an  NaC1 
gradient (0-0.5  M), several peaks absorbing at 280 nm were observed (Fig.  2). 
When  fractions were analyzed by dot  blot  analysis using  mAb-NSAP,  NSAP 
eluted from the column with 0.13-0.16  M NaCI. 
Those fractions containing NSAP were pooled and dialyzed against 25  mM 
piperazine HCI buffer, pH 5.5, before application to a Polybuffer Exchange 94 
chromatofocusing column. Elution of the chromatofocusing column with a  1:10 
dilution  of Polybuffer 74,  pH  4.0,  resolved the  sample  into  several discrete 
fractions (Fig.  3).  Dot blot analysis of these fractions using mAb-NSAP showed 
that  NSAP  was  eluted at  a  pI  of 4.75.  Dialysis and  lyophilization of NSAP  + 
A  B  C  D  E,  F  G  H  I  J  K 
,6  L 
FIGURE  1.  Western  blot analysis of culture  supernatant  of group  A  Streptococcus  pyogenes 
strain  A374 grown in CDM.  10-ml aliquots were removed at different times in the growth 
curve: .4, Oh;B,  1 h;C, 2h;D,  3h;E,  4h;F,  5h;G,  6h;H,  7h;I,  8h;J,  12h;K,  18h. 
Total protein was precipitated by addition of TeA to 10% (vol/vol). After washing, precipitates 
were  resolved by  SDS-PAGE and  transferred  to  nitrocellulose membranes.  Western  blot 
analysis was performed using mAb-NSAP as probe (see Materials and Methods). 702  STREPTOCOCCAL  NEPHRITIS-ASSOCIATED  PROTEIN 
TABLt  I 
Presence of NSAP in Streptococcal Strains as Detected by Western 
Blot Analysis  Using mAb-NSAP 
NSAP detected* at various 
Patient  times  ~ (h): 
Strain  M type  source* 
2  4  6  8 
F203D  1  APSGN  +  +  +  _+  __+ 
A207  2  APSGN  +  +  +  +  --- 
B512  4  APSGN  ÷  +  +  ___  + 
B974  4  APSGN  +  +  +  +  + 
B743  5  APSGN  ÷  +  +  --+  + 
tl2  12  APSGN  +  +  +  ___  __+ 
B923  12  APSGN  ÷  +  +  +  + 
A374  12  APSGN  +  +  +  +  + 
B438  18  APSGN  +  +  +  ___  __+ 
Gt8760  49  APSGN  ÷  +  ___  "4-  + 
A928  55  APSGN  ÷  +  ___  ___  "4- 
A995  57  APSGN +  +  +  _  ___ 
D480  1  APSGN-  -  -  -  - 
A830  3  APSGN-  -  -  -  - 
A964  5  APSGN-  -  -  -  - 
D313  12  APSGN-  -  -  -  - 
A992  18  APSGN-  -  -  -  - 
A456  36  APSGN-  -  -  -  - 
A315  50  APSGN-  -  -  -  - 
D438  55  APSGN-  -  -  -  - 
D438  55  APSGN-  -  -  -  - 
B931  2  APSGN-  -  -  -  - 
A915  4  APSGN-  -  -  -  - 
A552  9  APSGN-  -  -  -  - 
A834  49  APSGN-  -  -  -  - 
* APSGN  ÷ streptococcal strain obtained from patient diagnosed as having 
APSGN. APSGN- streptococcal strain obtained from patient diagnosed 
as not having APSGN. 
* +  indicates presence of intact  46  kD  NSAP;  -  indicates major protein 
is 43  kD, with traces of intact  46 kD; -  indicates the absence of NSAP 
in the supernatant of these cultures. 
Time of analysis of culture supernatant. 2  h  is early exponential, 4  h  is 
late exponential, 6  h  is early stationary, and 8 h  is late stationary phase 
of growth. 
fractions  resulted  in  a  yield  of  0.9  mg  NSAP  per  liter  of  culture  supernatant 
from  a  culture  grown  to  early  stationary  phase  of  growth  under  controlled  pH 
conditions.  Repeated  isolations  under  identical  growth  conditions  resulted  in 
yields of NSAP  that  varied  from  0.8  to  1.2  mg/liter  of culture  supernatant. 
As  this  purification  procedure  was  highly  reproducible,  subsequent  isolation 
of NSAP  was accomplished  by step-wise  salt elution  of the  (NH4)SO4  precipitate 
on  a  DEAE-Sepharose  6 B  anion-exchange  column.  When  0.1  M  increments  of 
NaCI  were  applied  to  the  anion-exchange  column,  all  the  NSAP  was  eluted  by 
0.2 M  NaCI  (Fig. 4). This  was confirmed  by Western  blot analysis of each  fraction 
eluted  with  different  molarities  of salt (Fig.  5). 
Figs. 4  and  5  summarize  tbe  isolation  of NSAP  from  an  (NH4)2SO4  precipitate 0.81 
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FIGURE  2.  DEAE-Sepharose 6  B chromatography of ammonium sulfate precipitate of cul- 
ture supernatant  of group A  Streptococcus pyogenes strain  A374.  Column was eluted with 50 
mM Tris-HCI buffer, pH 7.5, with an NaCI gradient of 0-0.5 M. Fractions were analyzed for 
absorbance at  280  nm (0------0), and  presence of NSAP by  dot blot analysis of individual 
fractions (I). 
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FIGURE  3.  Chromatofocusing profile of fraction eluted  with 0.2  M  NaCI  from a  DEAE- 
Sepharose 6  B column (see Fig. 2).  Column was monitored for protein at an absorbance of 
280 nm (0-------0); pH was monitored (  .....  ), and fractions were analyzed for the presence 
of NSAP by dot blot analysis (1~). 2-ml fi'actions were collected. 
of the culture supernatant by step-wise  salt elution  on a  DEAE-Sepharose  6B 
anion-exchange column, followed by fractionization on a PBE94 cbromatofocus- 
ing column. 
Amino-terminal  Sequence  and  Amino  Acid  Data  on  Purified  NSAP.  Amino- 
terminal sequence analysis was performed with the purified NSAP. The resultant 
sequence  through  residue  21  was compared  with  all  the  known  sequences  of 
proteins in the  Protein  Sequence Database  using the fast PS program  (20).  Of 
the 3384 proteins analyzed,  the amino-terminal sequence of streptokinase from 
group  C  streptococcus  was  identical  to  the  amino-terminal  sequence  of  the 
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FIC,  URE  4.  SDS-PAGE profile of fractions eluted  from  DEAE-Sepharose  6B-CI by batch- 
wise elution with  NaC1  in  50 mM  Tris-HCl buffer, pH  7.5.  Starting material was NH4SO~ 
precipitate  of culture  supernatant  of group  A  S.  pyogenes  strain  A374.  A,  sample  before 
application to column; B, fraction eluted with 0.1  M NaCI; C, fraction eluted with 0.2 M NaCI; 
D,  fraction eluted with 0,3  M  NaCI; E,  fraction eluted with 0.4 M  NaC1;  F,  fraction eluted 
from PBE chromatofocusing column at pH 4.75. 
FIGURE 5.  Western blot analysis of fractions eluted from DEAE-Sepharose 6 B column and 
PBE 94 chromatofocusing column. A, sample of NH4SO4 precipitate of supernatant of strain 
A374 S. pyogenes group A before application to DEAE column; B, fraction eluted~with 0.1  M 
NaCI; C, fraction eluted with 0.2  M  NaCI; D,  fraction eluted with 0.3  M  NaCI; E, fraction 
eluted with  0.4  M  NaC1;  F,  fraction from  PBE  94 chromatofocusing column  eluted at  pH 
4.75.  Nitrocellulose membrane was probed with mAb-NSAP (see Materials and Methods). 
10  20 
NSAP:  NH~-~e~A~a~G~y-Pr~-G~u-Tr~-Leu-Leu-Asp-Arg-Pr~-Ser~Va~-Asn-Asn~Ser-G~n-Leu-Va~-Va~-Ser- 
C-Skase: NH2-••e-Ala-G•y-Pr•-G•u-Trp-Leu-Leu•As•-Arg-Pr•-Ser-Va•-Asn-Asn-Ser-G•n-Leu•Va•-Val-Ser- 
FW.U~tE 6.  N-terminal sequence of NSAP isolated from group A Streptococcus, strain A374, 
compared to that of streptokinase isolated from group C Streptococcus, strain H46A. Group C 
streptokinase (Skase) sequence as reported by Jackson and Tang (29). JOHNSTON  AND  ZABRISKIE 
TABLE  II 
Amino Acid Composition of NSAP and Streptokinases Isolated  from 
Group A, C, and G Streptococci 
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Amino acid composition of streptokinases  isolated from: 
Amino  NSAP  Group A  Group C  Group G  acid 
1"  2  3  4  5  6  7  8 
Asx  55  62  59  57  58  56  57  67  55 
GIx  45  43  46  48  48  49  42  45  54 
Ser  26  27  25  23  26  22  24  26  22 
Gly  22  21  21  24  22  27  20  20  22 
His  12  12  10  9  11  9  9  9  8 
Arg  19  20  23  19  20  15  18  19  17 
Thr  27  27  27  29  27  29  26  28  27 
Ala  26  24  25  30  27  30  21  22  35 
Pro  17  22  20  20  20  25  21  21  19 
Tyr  19  23  21  19  21  18  20  21  16 
Val  26  26  28  27  26  25  20  23  30 
Met  4  4  5  5  5  6  4  4  5 
Cys  0  0  0  0  0  0  0  0  0 
Ile  18  19  21  22  20  19  20  22  22 
Leu  36  38  37  37  37  32  35  39  37 
Phe  15  17  16  16  16  15  14  15  14 
Lys  29  29  30  30  31  37  29  34  32 
Trp  ND  ND  ND  ND  ND  ND  2  1  ND 
Values represent the content of amino acids expressed  mole/mole protein based on a molecular 
weight of 46,000. ND, not determined. 
*  1-5, Gerlach and Kohler (30); 6, Brockway and Castellino (31); 7, Morgan and Henschen (32); 8, 
Gerlach and Kohler (30). 
When  the  amino  acid  analysis  of  purified  NSAP  isolated  from  group  A 
streptococcus,  strain  A374,  was compared  to the published  amino acid analysis 
of streptokinases  isolated from groups A, C, and G  streptococci, a close similarity 
was observed (Table II). 
Biochemical and Immunological Analyses of  Purified NSAP.  The amino-terminal 
sequence and amino acid analysis data indicated  that NSAP was a  streptokinase- 
like molecule, and might thus activate plasminogen to produce plasmin. This was 
tested  using  the  plasmin-specific  synthetic  substrate,  ~Val-Leu-Lys-p-nitroani- 
lide. When purified NSAP was incubated in the presence of human plasminogen, 
the  plasmin  substrate  was  cleaved  to  release  p-nitroanilide,  which  could  be 
measured spectrophotometrically.  Fig. 7 illustrates  the activity of purified NSAP 
in the presence and absence of human plasminogen.  Streptokinase,  isolated from 
group C  streptococcus strain  H46A  also activated plasminogen to form plasmin, 
which acted  upon  the  synthetic  substrate.  Both  NSAP and  streptokinase  alone 
did not cleave the plasmin substrate. 
Purified NSAP was also examined for its antigenic relatedness to streptokinase 
isolated  from  group  C  streptococcus  strain  H46A.  Enzyme-linked  immunoa- 
nalysis (Fig.  8a) showed that  NSAP isolated  from group A  streptococcus strain 
A374  shared  antigenic  determinants  with  streptokinase  from  Group  C  when 
tested with rabbit polyclonal antisera prepared  to either NSAP or streptOkinase. 0.6 
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FIGURE 7.  Plasminogen activation profile of purified NSAP and streptokinase  from group 
C streptococcus  strain  H46A.  Equivalent amounts (2 x  10  -J2 tool) of NSAP (O-------O)  and 
streptokinase  (O  O) were incubated with an equivalent amount of human plasminogen in 
the presence of the plasmin substrate D-Val-Leu-Lys-p-nitroanilide.  Identical amounts of NSAP 
(0  ....  O)  and  streptokinase  (O  ....  O)  were  also  incubated with  the  substrate  in the 
absence of plasminogen. Activity was monitored for 20 rain at 405 nm to measure the release 
of p-nitroanilide  from the substrate by the action of plasmin. 
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FIGURE 8.  Antigenic  analysis of purified NSAP and streptokinase from graup C streptococ- 
cus strain  H46A.  Varying amounts of NSAP (A) and streptokinase  (B) were immobilized to 
polystyrene  microtiter wells. Wells were  incubated with  standardized  dilutions of rabbit 
polyclonal antibody to NSAP (×), rabbit polyclonal antibody to streptokinase  (0) and mAb- 
NSAP (0). Alkaline phosphatase-conjugated'anti-primary  antibody was used as the secondary 
antibody. Each point represents the mean of triplicate determinations. 
However,  when  the  same  antibodies were  tested  against streptokinase isolated 
from group C  streptococcus strain H46A, only the polyclonal antibody raised to 
NSAP  and  streptokinase  from  group  C  reacted  with  purified  C-streptokinase 
(Fig. 8b); the mAb against NSAP did not recognize C-streptokinase, thus indi- 
cating that NSAP was antigenically different from the streptokinase from group 
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Discussion 
NSAP  was  purified  from  the culture supernatant  of group  A  Streptococcus 
pyogenes strain  374.  This strain  had been isolated from a  patient diagnosed as 
having APSGN. This protein, of molecular mass 46 kD was a major extracellular 
protein produced by this strain. From cultures grown to early stationary phase 
of growth, an average yield of 1 rag/liter of purified NSAP could be obtained. 
When the original  observations of Villareal et al.  (8)  were reassessed using 
immunological methods, it became evident that, as the culture entered stationary 
phase of growth, a second protein (43 kD) appeared in the supernatant. As the 
culture supernatants were tested for the presence of NSAP with an mAb raised 
against this 46 kD protein, it was apparent that the 43 kD species was most likely 
a cleaved product of NSAP sharing the same epitope. Previous observations by 
Johnston et al. (21) have indicated that this degradation of the NSAP molecule 
during  growth  of a  culture  was  possibly  the  result  of  enzymic activity  by 
streptococcal proteinase. It has been known for many years that the majority of 
group  A  streptococci  elaborate  an  extracellular  zymogen,  which,  under  the 
reducing conditions of growth  and  a  pH  of <6.5,  is  converted to  an  active 
mercaptoproteinase (22-24).  If the culture medium is maintained at a pH >6.8, 
this conversion of zymogen to proteinase is depressed. Thus, for optimum yields 
of NSAP, streptococci were grown in medium in which the pH was maintained 
between 6.8-7.0.  Furthermore, initial purification procedures used iodoaceta- 
mide to inactivate any reduced active form of the proteinase. This  lability of 
NSAP to enzymic degradation may explain the difficulties encountered by other 
investigators (8) in their attempts to isolate NSAP. 
The 46  and 43  kD species of NSAP are reminiscent of other streptococcal 
proteins implicated in APSGN. Yoshizawa et ai. (25) have isolated, from a water 
soluble fraction of disrupted streptococcal strains isolated from APSGN patients, 
a protein of molecular mass 43 kD. This protein had a pI of 4.7, and has been 
associated within a  restricted spectrum of group A  streptococcal isolates. This 
protein,  known as the preabsorbing antigen, was detected in  the glomeruli of 
kidney biopsies from APSGN patients, and in animals perfused with this antigen 
(26).  In  a  separate  study, Ohkuni  et al.  (27)  reported a  pI  of 4.7  for  NSAP 
isolated by elution from preparative SDS-PAGE gels. This value corresponds to 
the  value  (pI,  4.75)  reported  here  for  NSAP  isolated  by  cbromatofocusing. 
Lange et al. (28) have described an antigen, endostreptosin (ESS) derived from 
the cytoplasm of groups A, C, and G streptococci. This antigen had a molecular 
mass of 49 kD. All antigens described above have been fo,und in the glomerular 
tissues of APSGN patients. This correlation may suggest that ESS is the prese- 
creted form of NSAP,  that  is,  NSAP plus a  signal peptide;  the preabsorbing 
antigen  may be  the  degraded  form  of NSAP,  and  NSAP  as  described  here 
represents the native extracellular form. 
When purified NSAP was subjected to amino acid analysis and the data was 
compared to that known for other streptococcal extracellular products, it became 
apparent that NSAP shared an amino acid composition profile with streptokinases 
isolated from groups A, C, and G streptococci. When the amino-terminal amino 
acids of NSAP were compared to those of streptokinase isolated from a group C 
streptococcus (29-32),  both  molecules possessed the same first 21  amino acid 708  STREPTOCOCCAL  NEPHRITIS-ASSOCIATED  PROTEIN 
residues. Thus, it became apparent that NSAP was structurally similar to strep- 
tokinase. 
Streptokinase is  known as a  potent  activator  of plasminogen (33),  wherein 
plasmin, a proteolytic enzyme, is generated. When purified NSAP was incubated 
in  the  presence of the  plasmin-specific synthetic tripeptide,  o-Val-Leu-Lys-p- 
nitroanilide, it activated plasminogen on a mole/mole basis comparable to strep- 
tokinase from group C streptococci. Thus, NSAP not only possessed structural 
but functional similarity to streptokinase. 
Numerous investigators, most notably Weinstein (34), and Gerlach and Kohler 
(30,  35)  have  shown  that  streptokinases  isolated  from  groups  A,  C,  and  G 
streptococci are antigenically different from each other. Dillon and Wannamaker 
(36) found two physically and immunologically different types of streptokinases 
produced by  different group  A  streptococci,  and  these  were  different from 
streptokinase from group C streptococci. Houba and Hana (37) suggested that 
one group A streptokinase lacked some antigenic determinant present in group 
C  streptokinase, and differed from those group A  streptokinases described by 
Dillon and Wannamaker (36). With this in mind, NSAP was compared to group 
C streptokinase using polyclonal antisera to NSAP and to group C streptokinase 
and an  mAb against  NSAP.  It  became evident that  NSAP  had  an  antigenic 
domain (assuming the mAb recognized a single epitope) that differed from that 
of the group C streptokinase. Dillon and Wannamaker (36) also suggested that 
streptokinase may share antigenic domain(s) involved in the plasminogen activa- 
tion site, but distinct variable serological domains. Thus, when NSAP is compared 
to other group A streptokinases, it may become apparent that NSAP is an unique 
streptokinase, in  that  some domains of the molecule are involved in  classical 
streptokinase activities,  and  other domains  may be  involved  in  initiating  the 
nephritogenic process. 
When  viewed in  the  context  of the  human  disease,  the  known  biological 
properties of NSAP (streptokinase) could account for many of the clinical and 
pathological findings in APSGN. For example, streptokinase activates plasmino- 
gen (33, 38), which in turn may stimulate certain cells to proliferate and release 
cellular inflammatory products (39). In APSGN hypercellularity and endothelial 
cell proliferation in the glomeruli are pathological hallmarks of the disease (40). 
The presence of low complement serum levels and renal complement deposition 
seen in  APSGN could represent the known ability of plasmin,  resulting from 
streptokinase-plasminogen  interaction,  to  activate  certain  components of the 
complement cascade (41-43). In addition, the low serum complement levels seen 
in APSGN patients are often associated with disturbances in clotting times, an 
observation consistent with the known disturbances of the clotting pathways (44) 
after streptokinase activation of plasminogen. Finally, deposition of fibrin prod- 
ucts is commonly seen in the biopsies of APSGN (45), possibly reflecting depo- 
sition of fibrin split products after streptokinase activation of plasminogen (46). 
Given these observations, how would the molecule exert its effects in view of 
the common occurence of streptokinase antibodies in  the human population? 
Ohkuni et al. (9) indicated that, while ~95%  of APSGN patients had antibody 
to NSAP, only 15% of rheumatic fever patients had this antibody. More recently, 
using the more sensitive ELISA method, examination of the sera of 100 normal JOHNSTON AND  ZABRISKIE  709 
Trinidad school children, 5-8 yr of age (the susceptible age group) revealed that 
~5% of the children had no antibody to NSAP (unpublished observations). Thus, 
we propose that these individuals would be at highest risk of contracting APSGN, 
since the biological activities of NSAP would not be blocked. With increasing 
age, the number of children without detectable antibody to NSAP would de- 
crease, and thus the risk of contacting APSGN diminish with age. The observa- 
tion that antibody to  NSAP  was  found in  the  sera  of ~95%  of the  APSGN 
patients (9)  also correlates quite well with the clinical observation that second 
attacks of APSGN are extremely rare. 
Work now in progress in this laboratory indicates that, when purified NSAP 
is  injected  into  experimental  animals,  deposition  of complement and  NSAP 
antigen, host antibody, and glomerular hypercellularity are seen in the glomeruli 
of these animals. 
Summary 
We  report  the  isolation  and  purification of the  nephritis  strain-associated 
protein (NSAP) first described by Villareal et al. (8).  Amino acid analysis, and 
determination of the first 21  amino-terminal amino acids indicated that this 46 
kD protein is a streptokinase. Biochemical analysis confirmed that NSAP could 
act as a plasminogen activator; immunological investigations indicated that NSAP 
is antigenically different from streptokinase from group C  streptococcus, and 
possibly represents a unique streptokinase. It is this uniqueness that may contrib- 
ute to the role of NSAP in the pathogenesis of acute poststreptococcal glomer- 
ulonephritis. 
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